Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Sab Biotherapeutics Inc WT (SABSW)

Sab Biotherapeutics Inc WT (SABSW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes GlobeNewswire - Tue Jul 7, 7:00AM CDT

MIAMI, July 07, 2026 (GLOBE NEWSWIRE) -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage...

SABSW : 0.0111 (-35.84%)
SABS : 3.63 (+3.42%)
SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting GlobeNewswire - Fri May 29, 7:00AM CDT

MIAMI, May 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq:  SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0111 (-35.84%)
SABS : 3.63 (+3.42%)
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights GlobeNewswire - Tue May 12, 6:30AM CDT

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027 Reported additional Phase...

SABSW : 0.0111 (-35.84%)
SABS : 3.63 (+3.42%)
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET GlobeNewswire - Tue May 5, 7:30AM CDT

MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0111 (-35.84%)
SABS : 3.63 (+3.42%)
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026 GlobeNewswire - Wed Apr 22, 6:00AM CDT

All 4 T1D participants receiving SAB-142 showed C-peptide preservation with 3 of the 4 participants showing a super responder profile concomitant with T cell exhaustion T1D participants receiving...

SABSW : 0.0111 (-35.84%)
SABS : 3.63 (+3.42%)
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress GlobeNewswire - Wed Apr 15, 7:00AM CDT

MIAMI, April 15, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0111 (-35.84%)
SABS : 3.63 (+3.42%)
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire - Thu Mar 19, 3:01PM CDT

MIAMI, March 19, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0111 (-35.84%)
SABS : 3.63 (+3.42%)
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire - Tue Mar 17, 9:46PM CDT

MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0111 (-35.84%)
SABS : 3.63 (+3.42%)
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire - Tue Mar 17, 3:01PM CDT

MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type...

SABSW : 0.0111 (-35.84%)
SABS : 3.63 (+3.42%)
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes GlobeNewswire - Tue Mar 10, 6:31AM CDT

Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10,...

SABSW : 0.0111 (-35.84%)
SABS : 3.63 (+3.42%)

Barchart Exclusives

The $2.9 Billion Reason UTZ Stock Is Up Today Barchart - 10 minutes ago
UTZ stock soars as Intersnack agrees to take the snacks company private in a $2.9 billion deal. Here’s why the German firm is paying a massive premium for UTZ shares. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.